– Ionis-authored research also recognized with Paper of the Year honor
CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that Frank Bennett, Ph.D., Ionis’ executive vice president and chief scientific officer, has been awarded the 2020 Lifetime Achievement Award by the Oligonucleotide Therapeutics Society (OTS). Dr. Bennett was recognized by the OTS Award Committee for his important contributions to basic science and for being instrumental in the development of antisense oligonucleotide drugs that modulate splicing to correct severe genetic disease.
A founding member of Ionis, Dr. Bennett is responsible for continuing to advance antisense technology and expanding Ionis’ drug discovery platform. He is also the franchise leader for neurological programs at Ionis. Dr. Bennett is a co-recipient of the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of
SAN DIEGO, Oct. 1, 2020
SAN DIEGO, Oct. 1, 2020 /PRNewswire/ — This year’s annual Oligo Meeting was tremendously successful, with over 1,000 people representing 29 countries in attendance. The annual meeting brings together oligonucleotide experts from all over the world for cross-disciplinary exchange, fostering the development of ground-breaking new ideas. Areas of expertise span from chemistry and delivery to biology, immunology, and clinical medicine. Although unable to meet in person, moving the annual meeting to a virtual platform this year afforded an excellent opportunity for sharing the impressive work being done in our field.
A highlight of this years’ meeting was the announcement of two Lifetime Achievement Award winners, Dr. Ryszard Kole and Dr. Frank Bennett. The Award Committee felt it was fitting to have these individuals as a “double
Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held virtually from September 27th to 30th, 2020.
Sapreme is developing macromolecule delivery methods based on compounds that release therapeutic cargo from the endo-lysosome, improving access to intracellular targets and enhancing the therapeutic window for these therapeutics. Current macromolecular biologics rely on receptor-mediated endocytic uptake into the endosome and inefficient passive release from these vesicles into the cell to achieve therapeutic efficacy. The company’s presentations demonstrate that Sapreme’s SPT001 compound improves intracellular release of targeted antisense oligonucleotides (ASOs) and thereby also their therapeutic efficacy. In addition to ASOs, SPT001 has also been demonstrated to enhance delivery of other targeted payloads such as antibody-conjugated toxins.
“The data presented today